Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clenbuterol - CuraSen Therapeutics

Drug Profile

Clenbuterol - CuraSen Therapeutics

Alternative Names: CST-103

Latest Information Update: 27 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CuraSen Therapeutics
  • Class Antiasthmatics; Antibronchitics; Ethanolamines
  • Mechanism of Action Beta-adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Parkinson's disease

Most Recent Events

  • 21 Dec 2023 Gianni Soraru in collaboration with Mario Negri Institute for Pharmacological Research plans a phase II trial for (Spinal and Bulbar Muscular Atrophy in January 2024 (NCT06169046)
  • 17 Nov 2021 Pharmacodynamics and adverse events data of a phase II trial in Parkinson's disease presented at 14th Annual Clinical Trials on Alzheimer’s Disease (CTAD) conference
  • 28 Jun 2021 CuraSen Therapeutics plans a phase II CLIN-012 trial for Parkinson's Disease (Combination therapy) in Australia (PO, Capsule) in September 2021 (NCT04935762)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top